For decades, the diagnosis of esophageal cancer was often met with a sense of clinical resignation. Characterized by aggressive progression and historically poor outcomes, the disease left clinicians with limited therapeutic options, often forcing a choice between grueling chemoradiation and invasive surgery. However, the landscape of oncology has shifted dramatically over the past seven years, driven by the rise of immunotherapy. What began as a “glimmer of hope” in the late 2010s has matured into a robust, multi-faceted standard of care that is redefining how we approach resectable esophageal and gastroesophageal junction (GEJ) cancers.
The Evolution of Immunotherapy: From Salvage to Standard
The journey of immunotherapy in this space began with the FDA’s strategic shift toward accelerated approvals. In 2019, the agency granted accelerated approval to pembrolizumab (Keytruda) for patients with previously treated, recurrent, locally advanced, or metastatic esophageal squamous cell carcinoma. This decision marked a watershed moment, signaling that the immune system could be effectively harnessed to combat a tumor type long considered resistant to conventional systemic therapies.
Nivolumab (Opdivo) followed suit a year later, further cementing the role of PD-1 inhibition in the metastatic setting. As these agents proved their efficacy in patients with advanced disease, the clinical focus naturally pivoted toward moving these therapies into earlier lines of treatment. Pembrolizumab was subsequently approved for first-line use in combination with chemotherapy for unresectable locally advanced or metastatic esophageal adenocarcinoma, effectively bridging the gap between palliative care and curative intent.
A Chronological Shift in Clinical Practice
The progression of immunotherapy has been rapid and sequential:
- 2019–2020: Regulatory approval of PD-1 inhibitors for recurrent or metastatic disease.
- 2021–2022: Integration of immunotherapy into first-line systemic regimens for metastatic adenocarcinoma.
- 2023–2024: The emergence of positive data from phase II and III trials, leading to the adoption of immunotherapy in the neoadjuvant (pre-surgical) and perioperative (pre- and post-surgical) settings.
The most recent iteration of the National Comprehensive Cancer Network (NCCN) esophageal guidelines represents the culmination of this evolution. As of early 2024, the guidelines list the combination of FLOT chemotherapy—a regimen consisting of 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel—paired with the PD-L1 inhibitor durvalumab (Imfinzi) as a preferred regimen. This recommendation applies to a wide spectrum of patients, including those with varying PD-L1 Combined Positive Scores (CPS) or Tumor Area Positivity (TAP) levels, as well as those with node-negative tumors or diffuse-type esophagogastric junction adenocarcinoma.
Supporting Data: The Case for Perioperative Therapy
The momentum for perioperative therapy—the practice of administering systemic treatment before and after surgery—has been fueled by both comparative trials and the limitations of traditional chemoradiation.
For years, the gold standard for resectable esophageal cancer was FLOT-based chemoradiation followed by surgery. However, the ESOPEC trial challenged this paradigm. By demonstrating that perioperative chemotherapy improved overall survival (OS) by nearly 2.5 years compared to neoadjuvant chemoradiation, the study forced a re-evaluation of surgical protocols. While ESOPEC had limitations—including patient selection bias and the lack of adjuvant immunotherapy—it acted as a catalyst for a broader shift in clinical behavior.
The MATTERHORN trial provided the definitive nudge for many clinicians. By incorporating immune therapy into the perioperative regimen, the trial demonstrated superior overall survival compared to chemotherapy alone. According to Dr. Shadia Jalal of the Indiana University Simon Comprehensive Cancer Center, this data effectively shifted the consensus. "Since the MATTERHORN results, we have really moved toward perioperative chemotherapy with immune therapy as the new standard," Dr. Jalal noted.
The Success of Biomarker-Driven Subgroups
While the general population has seen benefits, the most striking results have emerged in patients with microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors. Several phase II trials have consistently shown high pathologic complete response (pCR) rates in this cohort:
- NEONIPIGA Trial: A study of 32 patients using nivolumab and ipilimumab reported a pCR rate of 58.6% and a histological response rate of 72.4%.
- INFINITY Trial: Focused on 18 patients, this study utilized tremelimumab and durvalumab, achieving a 60% pCR rate and an 80% histological response rate.
- DANTE Trial: A study of 23 patients comparing FLOT plus atezolizumab against FLOT alone, confirming that the addition of immunotherapy led to higher response rates and a high rate of successful surgical resection.
Official Perspectives and Clinical Nuance
Despite these successes, the oncology community remains cautious, emphasizing that there is no "one size fits all" approach. Dr. Kei Muro of the Aichi Cancer Center Hospital has highlighted that while MSI-H/dMMR patients show clear, consistent benefits, the results in the broader, unselected patient population are more complex.
Large-scale trials like KEYNOTE-585 (1,000 patients) and ATTRACTION-5 (800 patients) have yielded mixed results. While KEYNOTE-585 met its pCR endpoint, it failed to demonstrate a statistically significant improvement in event-free or overall survival compared to chemotherapy alone. These discrepancies highlight the "noise" in clinical data—differences in chemotherapy backbones, regional variations in treatment standards, and variations in tumor biology.
Dr. Do-Youn Oh of Seoul National University Hospital, speaking at the ASCO annual meeting, noted the geographical divide in global standards. While North America and parts of Europe have embraced FLOT-based perioperative immunotherapy, Asian practices often rely on different standards, such as CAPOX or S-1, combined with D2 lymphadenectomy. This variation begs a crucial question: Is the current evidence robust enough for universal, global implementation?
"Many studies are ongoing, and long-term survival outcomes are still pending," Dr. Oh stated. "There is an active debate regarding whether pathologic complete response is a truly reliable surrogate for long-term survival in gastric and esophageal cancers."
Implications for Future Care: The Era of Precision Oncology
The future of esophageal cancer treatment likely lies in the refinement of patient selection rather than the broad application of immunotherapy. The "one-size-fits-all" model is rapidly being replaced by a biomarker-informed strategy.
Current research is moving toward a deeper understanding of the tumor microenvironment (TME). Dr. Oh points to the identification of five distinct "ecosystem types" in resectable gastric and esophageal cancers. By analyzing these types, clinicians may soon be able to predict which patients will respond to chemotherapy alone, which will require chemoimmunotherapy, and which might be candidates for novel combinations involving anti-angiogenic agents.
Furthermore, the integration of multi-omic data—combining genomic, transcriptomic, and proteomic profiling—promises to categorize patients into specific subtypes. This move toward personalized medicine aims to spare patients from the toxicities of ineffective treatments while ensuring that those with high-risk, immune-sensitive tumors receive the most aggressive and effective therapies available.
Conclusion: A Measured Optimism
The evolution of esophageal cancer treatment over the last seven years is a testament to the power of immunotherapy. By moving these agents from the end-stage palliative setting to the curative perioperative setting, the medical community has fundamentally altered the trajectory of the disease for thousands of patients.
However, the road ahead requires rigorous scrutiny. The variability in trial outcomes underscores the necessity of continued, high-quality research that accounts for tumor heterogeneity and biological subtypes. As clinicians balance the promise of new, high-response regimens with the necessity of ensuring long-term survival benefits, the field is clearly moving toward a more nuanced, biomarker-driven future. The “glimmer of hope” has indeed grown into a substantial clinical fire, but the work of turning that fire into a consistent, universal cure is only just beginning.
